CSTONE PHARMA-B
- Country
- 🇭🇰Hong Kong, China
- Ownership
- -
- Established
- 2018-12-13
- Employees
- 164
- Market Cap
- -
- Website
- http://www.cstonepharma.com
- Introduction
Cornerstone Pharmaceutical was created to meet the needs of cancer patients and focuses on developing and commercializing innovative tumor immunotherapy and molecular-targeted drugs. Since its establishment 3 years ago, the company has assembled a world-class management team with rich experience in preclinical research, clinical development and commercializa...
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT04194801
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Nanfang Hospital,, Guangzhou, Guangdong, China
🇨🇳Shanghai East Hospital, Shanghai, Shanghai, China
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 534
- Registration Number
- NCT04194775
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳Beijing You'an Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The 900th Hospital of Joint Logistic Support Force of PLA, Fuzhou, Fujian, China
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 540
- Registration Number
- NCT04187352
- Locations
- 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳Tianjin Medical University General Hospital, Tianjin, Tianjin, China
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT04176393
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Study of CS3002 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT04162301
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Peninsula and South Eastern Haematology and Oncology Group, Heidelberg, Victoria, Australia
A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 107
- Registration Number
- NCT03809767
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
🇨🇳The First Hospital of Jilin University, Changchun, China
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 479
- Registration Number
- NCT03802591
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 479
- Registration Number
- NCT03789604
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of CS1001 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03744403
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT03736850
- Locations
- 🇨🇳
People's Liberation Army 307 Hospital, Beijing, Beijing, China